What was the market valuation of the China patient derived-xenograft-model market in 2024?

The market valuation was $18.97 Million in 2024. Read More

What is the projected market valuation for the China patient derived-xenograft-model market by 2035?

The projected valuation for 2035 is $74.99 Million. Read More

What is the expected CAGR for the China patient derived-xenograft-model market during the forecast period 2025 - 2035?

The expected CAGR is 13.31% during the forecast period 2025 - 2035. Read More

Which tumor type segment had the highest valuation in 2024?

The Breast Cancer segment had the highest valuation at $4.25 Million in 2024. Read More

What are the two primary model types used in the China patient derived-xenograft-model market?

The primary model types are Mice and Rats, with valuations of $9.48 Million and $9.49 Million respectively in 2024. Read More

Which end-user segment contributed the most to the market in 2024?

The Pharmaceutical and Biopharmaceutical Companies segment contributed the most, with a valuation of $7.59 Million in 2024. Read More

Who are the key players in the China patient derived-xenograft-model market?

Key players include Charles River Laboratories, Crown Bioscience, Horizon Discovery, and others. Read More

What is the projected growth trend for the Breast Cancer segment from 2024 to 2035?

The Breast Cancer segment is projected to grow from $4.25 Million in 2024 to $17.0 Million by 2035. Read More

How does the valuation of the Other Cancer segment compare to that of Pancreatic Cancer in 2024?

In 2024, the Other Cancer segment was valued at $4.3 Million, while Pancreatic Cancer was valued at $2.84 Million. Read More

What is the significance of the projected market growth for the China patient derived-xenograft-model market?

The projected growth indicates a robust expansion, with the market expected to reach $74.99 Million by 2035. Read More

China Patient Derived Xenograft Model Market

ID: MRFR/HC/50977-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

China Patient-Derived Xenograft Model Market Research Report By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer), By Model Type (Mice, Rats) andBy End-User (Pharmaceutical, Biopharmaceutical Companies, Academic & Research Institutes, CROs, CDMOs) - Growth & Industry Forecast 2025 To 2035

China Patient Derived Xenograft Model Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Tumor Type (USD Million)
  1. 4.1.1 Lung Cancer
  2. 4.1.2 Pancreatic Cancer
  3. 4.1.3 Prostate Cancer
  4. 4.1.4 Breast Cancer
  5. 4.1.5 Other Cancer
2. 4.2 Chemicals and Materials, BY Model Type (USD Million)
  1. 4.2.1 Mice
  2. 4.2.2 Rats
3. 4.3 Chemicals and Materials, BY End-user (USD Million)
  1. 4.3.1 Pharmaceutical and Biopharmaceutical Companies
  2. 4.3.2 Academic & Research Institutes
  3. 4.3.3 CROs & CDMOs
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Charles River Laboratories (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Crown Bioscience (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Horizon Discovery (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 OncoOne (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 The Jackson Laboratory (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 XenoTech (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Celerion (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 CureMetrix (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY TUMOR TYPE
3. 6.3 CHINA MARKET ANALYSIS BY MODEL TYPE
4. 6.4 CHINA MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
11. 6.11 CHEMICALS AND MATERIALS, BY TUMOR TYPE, 2024 (% SHARE)
12. 6.12 CHEMICALS AND MATERIALS, BY TUMOR TYPE, 2024 TO 2035 (USD Million)
13. 6.13 CHEMICALS AND MATERIALS, BY MODEL TYPE, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY MODEL TYPE, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TUMOR TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY MODEL TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Chemicals and Materials Market Segmentation

Chemicals and Materials By Tumor Type (USD Million, 2025-2035)

Lung Cancer
Pancreatic Cancer
Prostate Cancer
Breast Cancer
Other Cancer

Chemicals and Materials By Model Type (USD Million, 2025-2035)

Mice
Rats

Chemicals and Materials By End-user (USD Million, 2025-2035)

Pharmaceutical and Biopharmaceutical Companies
Academic & Research Institutes
CROs & CDMOs

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”